Trial Profile
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Eluvixtamab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 31 May 2022 Status changed from recruiting to discontinued.
- 03 Mar 2022 Planned End Date changed from 3 Jun 2023 to 2 Aug 2023.
- 03 Mar 2022 Planned primary completion date changed from 3 Jun 2023 to 2 Aug 2023.